Compare AbCellera Biologics Inc (ABCL) vs TKO Group Holdings Inc (TKO) Price & Performance

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

TKO trades at $186.56, down 0.39% on the day, with a bullish technical signal and strong analyst support. The company reported record Q2 2026 revenue of $1.55 billion (up 18% year-over-year) and raised full-year guidance, though it missed EPS estimates. Valuation ratios are elevated with a P/E of 66.46, but profitability metrics show improvement. Recent corporate actions include an $800 million share repurchase and a $0.79 dividend payment.

The outlook is positive driven by media rights growth and live events, with a consensus price target of $228.17 implying 22% upside. Risks include earnings volatility and institutional selling. Wall Street sentiment remains strongly bullish with 89% buy ratings.